Safety Study of ASONEP (Sonepcizumab/LT1009) to Treat Advanced Solid Tumors
NCT00661414
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
37
Enrollment
INDUSTRY
Sponsor class
Conditions
Solid Tumors
Interventions
BIOLOGICAL:
ASONEP (sonepcizumab/LT1009)
Sponsor
Lpath, Inc.